Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 17/20 | 0.52 |
| ▸ | AR | P10275 | 7/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5503103 | 0.81 | PGR (0.60) | PGRNR3C1ARNR3C2 | |
| SCHEMBL5508304 | 0.80 | PGR (0.60) | PGRNR3C1ARNR3C2 | |
| SCHEMBL5650830 | 0.78 | PGR (0.58) | PGRNR3C1ARNR3C2 | |
| SCHEMBL5505736 | 0.77 | NR3C1 (0.59) | PGRNR3C1ARNR3C2 | |
| SCHEMBL5501612 | 0.75 | NR3C1 (0.66) | PGRNR3C1ARNR3C2 | |
| SCHEMBL5508824 | 0.74 | NR3C1 (0.69) | PGRNR3C1ARNR3C2 | |
| SCHEMBL5500302 | 0.72 | NR3C1 (0.49) | PGRNR3C1ARNR3C2 | |
| SCHEMBL5500939 | 0.72 | NR3C1 (0.55) | PGRNR3C1ARNR3C2 | |
| SCHEMBL5504610 | 0.72 | NR3C1 (0.53) | PGRNR3C1ARNR3C2 | |
| SCHEMBL5503354 | 0.71 | NR3C1 (0.61) | PGRNR3C1ARNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | claimed |
| EP-1778233-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2006019716-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | disclosed |
| EP-1778233-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006019716-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | CASR, GRK2, RYR2 | PGR 953/4885NR3C1 533/4885AR 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.